Quipt Home Medical (US:QIPT)2025-12-15 12:51Revenue Performance - Q4 2025 revenue was $68.3 million, an 11% increase from $61.3 million in Q4 2024, with a sequential organic growth of 5% from Q3 2025[5] - Fiscal year 2025 revenue was $245.4 million, slightly down from $245.9 million in fiscal year 2024[5] - Recurring revenue for Q4 2025 accounted for 80% of total revenue, driven by the growth in the resupply platform[5] Profitability Metrics - Adjusted EBITDA for Q4 2025 was $14.9 million, representing 21.8% of revenues, compared to $13.4 million (21.9%) in Q4 2024, marking an 11% increase[5] - Adjusted EBITDA for fiscal year 2025 was $55.9 million (22.8% of revenue), down 3% from $57.7 million (23.5%) in fiscal year 2024[5] - Net loss for Q4 2025 was ($3.6) million, or ($0.08) per diluted share, compared to ($2.9) million, or ($0.07) per diluted share in Q4 2024[5] Customer Growth - The customer base increased by 10% year over year to 346,000 unique patients served in fiscal year 2025[5] - Unique set-ups/deliveries increased by 7% to 917,000 in fiscal year 2025, including 486,000 respiratory resupply set-ups[5] Cash Flow and Financial Health - Cash flow from operating activities was $37.7 million for the year ended September 30, 2025, compared to $35.4 million for the previous year[5] - The Company maintains a conservative balance sheet with a Net Debt to Adjusted EBITDA Leverage Ratio of 1.8x[5]